

## DAFTAR PUSTAKA

- Abenovali,L.,Chorpechot,C.,Paupon, R. 2007. *Elastography In Hepatology*. Canadian Journal gastroenterology.vol 21:839-3. <https://www.ncbi.nlm.nih.gov>
- Abraldes, G.J.,Albillos, A., Banares, R, Turnes, J.,Gonzalez, R., Garcia,J., *et al.* 2009. *Simvastatin Lowers Portal Pressure In Patients With Cirrhosis And Portal Hypertension: A Randomized Controlled Trial*.Gastroenterology;136 : 1651-7
- Abraldes, G.J.,Villanueva, C., Aracil, C., Turnes,J., Guerra,M., Genesca, J., *et al.* 2016. *Addition of simvastatin to standart therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis*. .Gastroenterology;150: 1160-1170
- Ambapkar, S., shetty, N., Dwivedy, A.2016. *Statins Induced Rhabdomyolisis*.Journal of the association of physicians of India.vol: 64
- Anggoro, S. 2014. Rhabdomyolisis. In: AW Sudoyo, B Setiyohadi, I Alwi, M Simadibrata, S Setiati, editor. *Buku Ajar Ilmu Penyakit Dalam.4th Ed.* Jakarta: Pusat Penerbitan Departemen Ilmu Penyakit Dalam Fakultas Kedokteran Universitas Indonesia; P. 3560-6
- Azer,S.A., Katz,J. 2010. Esophageal Varices. Available from: <http://emedicine.medscape.com/article/175248-overview>
- Bataller, R.,Brenner, D. 2005. *Liver Fibrosis*. The Journal of Clinical Investigation. <http://www.jci.org>. Volume 115 Number 2
- Bays, H.,Cohen, D., Chalsani, N.,Harrison, S. An assesstment by the statin liver safety task force:4014 update. Journal of clinical lipidology, Vol.8: S47-S57.
- Benyon, Iredale., 2000., *Is Liver Fibrosis Reversible*. Gut medical journal. Vol: <http://www.gut.bmj.com>
- Botta, F., Giannini, E., Romagnoli, P., A. Fasoli. 2003. MELD scoring system is useful for predicting prognosis in patients with liver cirrhosis and is correlated with residual liver funtion : a European study. *Gut* ; 52 : 134-139
- Canbay, A., Friedman, S., Gores, G.J. 2004. Apoptosis: the nexus of liver injury and fibrosis. *Hepatology*, 39, 273-278. <https://www.ncbi.nlm.nih.gov>
- Canbay, A., Higuchi, H., Bronk, SF., Taniai, M., Sebo, TJ., Gores, G.J. (2002). Fas enhances fibrogenesis in the bile duct ligated mouse: a link between apoptosis and fibrosis. *Gastroenterology*, 123, 1323-1330.
- Cahyono, S. 2014. *Tatalaksana Klinis Di Bidang Gastro Dan Hepatologi*. Sagung Seto; Jakarta.
- Causevic, A., Ramosevac., Semiz, S. 2013. Drug interaction with statins. *Acta Pharm.* 63; 277-16.
- Cobbold, J, F., Morin, S., Robinson, T. 2007. Transient Elastography For The Assestment Of Chronic Liver Disease: Ready For Clinic. *World Journal Gastroenterology*. [www.wjgnet.com](http://www.wjgnet.com)

- Cohen-Naftaly, M., Friedman, SL. 2011. Current status of novel antifibrotic therapies in patients with chronic liver disease. *Therapeutic Advances in Gastroenterology*, 4(6), 391-26.
- Dahlan, M.S., 2009. *Besar Sampel dan cara pengambilan sampel dalam penelitian kedokteran dan kesehatan*. Salemba Medika. Jakarta.
- David, C., wolf. 2012. Cirrhosis. <http://www.emedicine.medscape.com/article/185856overview>.
- Durand, F. dan D. Valla. 2005. Assesment of the prognosis of cirrhosis : Child Pugh vs MELD. *Journal of Hepatology* 42 : Suppl (1) : 100-7
- D'Amico, G., Garcia-Tsao, G., Pagliaro, L. 2006. Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies. *Journal of Hepatology*. Vol. 44, No. 1, (Jan), pp. 217-31
- Dancygier, H. 2010. *Liver Cirrhosis in Clinical Hepatology. Principles and Practice of Hepatobiliary Diseases*; Vol. 2
- Dienstag, J.L., Goldin, R.D., Heathcote, E.J., Hann, H.W., Woessner, M., Stephenson, S., *et al.* 2003. Histological outcome during long-term lamivudine therapy. *Gastroenterology*, 124, 105-117.
- Ferri, F, Fred. 2015. *Chirrosis. Ferri's clinical Advisor* 2015. Elsevier Health Sciences: Philadelphia, hal. 297-2
- Flores, P., Soldan, M., Santos, U., Kunz, D., Mattos, D., Marchiori, R., *et al.* 2015. *Three month of simvastatin therapy vs placebo for severe portal hypertension in cirrhosis: A randomized controlled trial*. [www.elsevier.com](http://www.elsevier.com)
- Franchis, R., 2005. *Evolving concensus In Portal Hypertension*. Report Of The Baveno IV Consensus Workshop on Methodology Of diagnosis and Therapy In Portal Hypertension; 43: 167-9
- Friedmann, S. 2008. Mechanisms of Hepatic Fibrogenesis. *National Institute of Health. Gastroenterology*. May ; 134: 1655-14.
- Friedmann, Scott. 2003. *Liver Fibrosis-from bench to bedside*. *Journal Of Hepatology*. Vol. 38: 38-15.
- Goodman and Gilman's. 2008. *The Farmacological Basis Of Therapeutics eleventh edition*. McGraw-Hill Companies. United States Of America
- Guyton, A.C. Hall. 2007. *Buku Ajar Fisiologi Kedokteran*, ed 9, Penerbit Buku Kedokteran EGC, Jakarta
- Ha, C., Ha, J., Theriault, A., Bhagavan, N. 2009. Effect of statins on the secretion of human serum albumin in cultured HepG2 cell. *Journal Of Biomedical Science*, 16; 32. [www.jbiomedsci.com](http://www.jbiomedsci.com).
- Hadi, Sujono. 2012. *Gastroenterologi*. PT. Alumni. Bandung , 402-403, 613-647
- Hiedelbaugh, J.J., Sherbondy, M. 2006. Cirrhosis and Chronic Liver Failure :Part. II. Complication and Treatment. *American Family Physician journal*. vol. 74: 767-76. <https://www.aafp.org>

- Hirlan,. 2014.Ascites . In: AW Sudoyo, B Setiyohadi, I Alwi, M Simadibrata, S Setiati, editor. *Buku Ajar Ilmu Penyakit Dalam*.4th Ed. Pusat Penerbitan Departemen Ilmu Penyakit Dalam Fakultas Kedokteran Universitas Indonesia. Jakarta. P.1984-2
- Kashani,A., Landaverde,C., Medici,V., Rossaro,L. 2008. Fluid retention in cirrhosis:pathophysiology and management. *QJM:an international journal of medicine*, vol.101:71-14
- Katzung, B.G. 2002. *Farmakologi Dasar Dan Klinik*. Penerjemah dan Editor: Bagian Farmakologi Fakultas Kedokteran Universitas Erlangga. Edisi VIII.Penerbit Salemba Medika. Jakarta.Hal 433
- Kumar, S., Grace, ND., Qamar, AA. 2014. Statin Use in Patients with Cirrhosis: A Retrospective Cohort Study. *Digestive Diseasesa Sciences*;vol.59;1958–7.
- Kusumobroto, H. O. 2007. Sirosis Hati dalam Sulaiman, H. A., Akbar, H. N., Lesmana, L. A., Noer, M. S.,: *Buku Ajar Ilmu Penyakit Hati*, Edisi pertama, Jaya abadi, Jakarta, hal. 335-45.
- Knopp, R. 1999. The Benefits Of Statins In People Estabilished Cardiovascular Disease but with Cardiovascular Risk Factor: Meta Analysis Of Randomized Controlled Trial.The New England Journal Of Medicine. <http://www.nejm.org>
- Mach,F.,Ray,K.,Wiklund,O.,Corcini,A.,Catapano,A,L.,Bruckert,E.,et al.2018.Adverse effect of statin therapy perception vs. The evidence-focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. *European Heart Journal*. Vol:39.P:2526-13.
- Malizia, G,D' Amico,G.2016. *Statin in chirrhosis*. American association for the study of liver disease. *Hepatology*, Vol. 63, No.6
- Marcellin,P.,Gane,E.,Buti,M.,Afdhal,N.,Sievert,W.,Jacobson,I.M., *et al.* 2013. Regression of chirrhosis during treatment with tenovofir disoproxil fumarat for chronic hepatitis B: a 5 year open label follow up study. [www.pubmed.com](http://www.pubmed.com).
- Nurdjanah S. 2006.Sirosis hati. In: AW Sudoyo, B Setiyohadi, I Alwi, M Simadibrata, S Setiati, editor. *Buku Ajar Ilmu Penyakit Dalam*.4th Ed. Jakarta: Pusat Penerbitan Departemen Ilmu Penyakit Dalam Fakultas Kedokteran Universitas Indonesia; P. 443-6
- Papatheodoridis, V.,Cholangitas, E., Dimitriadou, E., Touloumi, G., Sevastianos, V., Archimandritis, A. 2005. MELD vs Child-Pugh and creatinin-modified Child-Pugh score predicting survival in patients with decompensated cirrhosis. *World Of Journal Gastroenterology*. [www.wjgnet.com](http://www.wjgnet.com)
- Price, S dan Wilson, L. *Patofisiologi Konsep Klinis Proses-Proses Penyakit*. EGC: jakarta
- Russo, W.M., Jacobson, M. 2004. How to use statins in patients with chronic liver disease. *Claveland clinic journal of medicine*. Vol 71
- Sadowitz, B, Maier, ,G., Gahtan,V. 2010. Basic Science Review: Statin Therapy Pielotropic Effect Of statin In Cardiovascular Disease.Vol.44:241-51 <http://www.sagepub.com>

- Samada, M., dan J.C. Hernandez. 2012. Prognostic factors for survival in Patient with Liver Cirrhosis dalam Abdeldayem, H., (Ed) Liver Transplantation-Basic Issues:125-138
- Sasidharan, M., Nistala, S.,Bhatia, S.,Rathi, P., Muruges, M.2012. Nutritional status and prognosis in cirrhotic patient. <http://www.tropicalgastro.com>
- Schomerus, H dan W. Hamster. 1998. Neuropsychological aspect of portal systemic encephalopathy. Metabolic Brain Disease;13:361-77. <https://www.springer.com>
- Sherlock, S. 2001. *The Portal Venous System and Portal Hypertension. Disease Of The Liver and Biliary System*. Blackwell science; P. 147-180
- Shirin.,H.,Sharvit,E.,Aeed,H,Gavish,D.,Bruck,R.2013. Atorvastatin and rosuvastatin do not prevent thioacetamide induced liver cirrhosis in rats. World Of Journal Gastroenterology.World Journal Gastroenterology 2013 January 14; 19(2): 241-7. <http://www.wjgnet.com>
- Stancu,C., Sina, A. 2001. Statins: Mechanism Of Action And Effects. Jcell, Mol.Med. Vol 4 No. 5. P: 378-9
- Stalnikowitz, D., Weissbrod, A. 2003. Liver Fibrosis and inflammation. Annals Of Hepatology:159-163
- Sulaiman,S,A.,Abdulrazzaq,H,A.2012.Neurological adverse drug reactions and statin therapy.international journal of pharmacy and pharmaceutical sciences.vol;4.P;446-449.
- Tandon, V., Bano, G.,Khajurian, Parlihar, A., Gupta, S.. 2004. Pleiotropic effect of statins.Indian Journal Pharmacology.vol 37. P: 77-85
- Tamargo,J.,Caballero,R.,Gomez,R.,Nunez,L,Vaquero,M.,Delpon,El. 2007. Lipid Lowering Therapy With Statins, a New Approach To Anti Arrhythmic Therapy
- Teisanu,A., Andrei,M., Arbanas,T., Nicolaie,T., Diculescu,M. 2012. Nutritional status in cirrhotic patients. Maedica. Journal of clinical medicine.vol:7.
- Yanez,M,R.,Agulla,J.,Gonzalez,R.,Sobrino,T.,Castillo,J. 2008. Review:Statins And Stroke In therapeutic Advanced In Cardiovascular Disease. [www.sagepublication.com](http://www.sagepublication.com)
- Yu, I.I., dan L. Abola. 2006. Predicting Prognosis Among Cirrhotic Patients :Child-Pugh Versus APACHE III Versus MELD Scoring Systems. Philadelphia Journal Gastroenterology; 2: 19-24.
- Zafra,C., Abalde,J,G, Turnes,J., Berzigotti, A., Fernandez, M., Rodes,J.,*et al*. 2004. Simvastatin Enhances Hepatic Nitric Oxide Production and Decrease The Hepatic Vascular Tone In Patients With Cirrhosis. Gastroenterology. Vol. 126: 749-6.